News | February 01, 2021
Sun Pharmaceutical Q3FY21 net profit at Rs. 1852.48 Cr
The company has reported total income of Rs.25699.68 crores during the 9 months period ended December 31, 2020.
The company has reported total income of Rs.25699.68 crores during the 9 months period ended December 31, 2020.
Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise
A PRV is a tradable voucher granted by the FDA to encourage the development of new treatments for rare pediatric diseases
India in the Changing Landscape of Life-Sciences Research & Development
His professional background also includes key experience at Matrix Labs and Sun Pharma
In her previous roles, Menon led significant digital transformation efforts, implementing predictive analytics, automation
FDA's withholding of the PRV was contrary to law because no drug product containing phenobarbital sodium was 'previously approved'
This strategic initiative aims to accelerate proof-of-concept of pipeline assets by streamlining R&D operations
Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025
Ukhade brings deep expertise in large-scale infrastructure planning, cross-functional leadership, and project innovation.
Subscribe To Our Newsletter & Stay Updated
